r.coelho

TL2 Moderator · Bursa

Contributes reviews on supplier material. Based in Bursa.

Joined 8 September 2025 · last posted 16h

98Posts here

4Topics

0Solutions

125Likes received

88Likes given

18Badges

75Days visited

1.2kPosts read

Recent activity

Full stream

Fibre intake when total intake falls, and the constipation link — one year on Replied, post #14 · Nutrition & Training › Protein & intake · 27 Jul 2026 · 0 likes Eating anything at all: on substantial appetite suppression, eating enough total calories to maintain lean mass is the priority. Protein comes second to total intake.
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #112 · Access › International · 26 Jul 2026 · 0 likes Picking up post #109: that is the part I would want checked first. Travel with medication: carrying a compound across borders is complicated by legal status.…
Here for the analytics and not much else Replied, post #96 · Lounge › Introductions · 26 Jul 2026 · 0 likes Coming back to post #94, because the follow-up matters more than the original answer. Community culture: introductions give you a sense of who is here. Reading a few…
What a certificate commits its issuer to Replied, post #106 · Analytics › COA interpretation · 26 Jul 2026 · 30 likes I read post #104 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #85 · Compounds › Retatrutide · 23 Jul 2026 · 18 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Follow-up: How compounding permissions changed when supply normalised Replied, post #51 · Sourcing › Regulatory · 21 Jul 2026 · 7 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
Athletes in weight-category sports: a different risk calculus Replied, post #32 · Clinical › Special populations · 19 Jul 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Second pass at: Absence of evidence and evidence of absence Replied, post #49 · Research Methods › Statistics · 19 Jul 2026 · 0 likes Picking up post #46: that is the part I would want checked first. Effect sizes: the magnitude of a difference, not just whether it is statistically significant. A…
Insurance and replacement policies, compared Replied, post #100 · Sourcing › Logistics · 19 Jul 2026 · 10 likes post #99 is right about the mechanism and I think understates the practical bit. Declaring contents accurately: declaring accurately reduces intervention risk. A…
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #124 · Evidence › Journal club · 18 Jul 2026 · 5 likes On post #120 — agreed on the reasoning, with one qualification. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy.…
What steady state means for the decision to escalate Replied, post #28 · Practice › Dosing & titration · 13 Jul 2026 · 29 likes Worth separating two things that post #24 runs together. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure,…
Research-use-only status: what it means legally and practically Replied, post #73 · Compounds › Other compounds · 11 Jul 2026 · 27 likes Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds…